Table 1.
Antiproliferative activity of doxorubicin, AgNMS complex and free NMS required to elicit total cell growth inhibition.
| Cell Line | TGI (µM ± SD) | ||
|---|---|---|---|
| Doxo | AgNMS | NMS | |
| U251 | >46 | 102.1 ± 51.9 | >800 |
| MCF-7 | 11.8 ± 9.3 | 26.3 ± 8.6 | >800 |
| NCI-ADR/RES | >46 | 157.3 ± 75.1 | 230.7 ± 129.2 |
| 786-0 | 3.4 ± 0.2 | 79.8 ± 22.8 | >800 |
| NCI-H460 | >46 | 116 ± 50 | >800 |
| PC-3 | 2.6 ± 1.6 | 22.8 ± 5.7 | >800 |
| OVCAR-03 | <0.046 | 22.5 ± 24.5 | 269.6 ± 66.8 |
| T-29 | <0.046 | 41.1 ± 8.2 | 234.2 ± 68.8 |
| K562 | 9.4 ± 10.9 | >600 | >800 |
| HaCaT | <0.046 | >600 | >800 |
Results (two independent experiments) expressed as concentration followed by standard deviation (SD) required to elicit total growth inhibition (TGI), calculated by sigmoidal regression using Origin 8.0 software. Samples: Doxo = doxorubicin (positive control, concentration range: 0.025–25 µg mL−1); AgNMS = silver nimesulide complex (concentration range: 0.25–250 µg mL−1); NMS = nimesulide (concentration range: 0.25–250 µg mL−1). Human tumor cell lines: U251 (glioblastoma); MCF-7 (breast, adenocarcinoma); NCI-ADR/RES (multidrug-resistant high-grade ovarian serous adenocarcinoma); 786-0 (kidney, adenocarcinoma); NCI-H460 (lung, non-small cell carcinoma); PC-3 (prostate, adenocarcinoma); OVCAR-03 (high-grade ovarian serous adenocarcinoma); HT29 (rectosigmoid adenocarcinoma); K562 (chronic myelogenous leukemia). Human non tumor cell line: HaCaT (immortalized keratinocyte).